Shilpa Medicare share jumps 14% on deal for production of Sputnik V vaccine
The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production
BusinessToday.In | May 17, 2021 | Updated 17:55 IST
Shilpa Medicare share rose 14 per cent to hit an intraday high of Rs 764.45 on BSE today after the company announced that its wholly owned subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a 3-year definitive agreement with Dr. Reddy's Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.